Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01291329

Intracoronary Human Wharton's Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With Acute Myocardial Infarction (AMI) — WJ-MSC-AMI  

ST-Elevation Myocardial Infarction Clinical Trial

Official title:
Phase 2 Study of Intracoronary Human Wharton's Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With ST-segment Elevation Acute Myocardial Infarction (AMI)

Clinical Trial Summary

The purpose of this study is to investigate the safety and efficacy of intracoronary human umbilical Wharton's jelly-derived mesenchymal stem cell (WJ-MSC) transfer in patients with ST-segment elevation acute myocardial infarction.

Clinical Trial Description

It has been demonstrated that MSCs have the potential to differentiate into cardiomyocytes both in vitro and in vivo. Several clinical trials have been performed using autologous bone marrow-derived MSCs, but the results of these trials have been unsatisfactory because of a low number of MSCs in older patients and in those with coronary heart disease. WJ-MSCs from the human umbilical cord matrix which are of epiblastic origin and contain both human embryonic stem cell (hESC) and human mesenchymal stem cell markers appear to have a number of important advantages: they do not raise ethical issues, are widely multipotent, are not tumorigenic, and are not immunogenetic. Because of a short population doubling time they can be rapidly scaled up in large numbers. We performed a double-blind, placebo-controlled, multicenter trial, randomly assigning 160 patients with acute ST-segment elevation myocardial infarction to receive an intracoronary infusion of WJ-MSCs or placebo medium into the infarct artery 4-7 days after successful reperfusion therapy. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01291329
Study type Interventional
Source Navy General Hospital, Beijing
Contact
Status Completed
Phase Phase 2
Start date February 2011
Completion date July 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT01864343 - Target Temperature Management In Myocardial Infarction - A Pilot Study N/A
Completed NCT00962416 - Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction (STEMI) Phase 4
Active, not recruiting NCT00927615 - Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO) N/A
Completed NCT03135275 - MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial N/A
Recruiting NCT02592694 - Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty Phase 4
Withdrawn NCT01991366 - Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
Completed NCT02158468 - Effect of Conditioning on Myocardial Damage in STEMI N/A
Completed NCT01197729 - OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - Registry N/A
Completed NCT06426537 - Colchicine's Efficacy in MI Patients: Comparing PCI and Non-Reperfusion Approaches Early Phase 1
Completed NCT01882179 - Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size Phase 3
Terminated NCT00719914 - A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks Phase 2
Completed NCT00952224 - Myocardial Salvage Assessed by Cardiovascular Magnetic Resonance - Impact on Outcome N/A
Completed NCT00378391 - European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry N/A
Withdrawn NCT04303377 - Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction Phase 2
Completed NCT03523624 - Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction
Completed NCT01531114 - PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus Phase 3
Active, not recruiting NCT01960933 - Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization N/A
Completed NCT00502528 - Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction Phase 2
Recruiting NCT02062554 - Brasilia Heart Study
Recruiting NCT04150016 - In-stent Repair and Vessel Reaction of STEMI Patients With OCT N/A